Maria San Basilio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria San Basilio has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Hernández
Pediatric Surgery Department, Hospital Universitario La Paz, 28046 Madrid, Spain
2 shared publications - Juan Carlos López Gutiérrez
Department of Pediatric Surgery, University Hospital La Paz, Madrid, Spain
2 shared publications - Karla Estefania-Fernandez
Department of Pediatric Surgery, La Paz Children’s University Hospital, 28046 Madrid, Spain
2 shared publications - Manuel Parrón‐Pajares
Skeletal dysplasia multidisciplinary Unit (UMDE) Hospital Universitario la Paz Madrid Spain
2 shared publications - Nelson Mauricio Buitrago SánChez
Sección de Radiología Pediátrica, Servicio de Radiodiagnóstico, Hospital Universitario La Paz, Madrid, Spain
2 shared publications - Paloma Triana
Department of Pediatric Surgery, Hospital Universitario La Paz, Paseo de la Castellana, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
Non-Involuting Congenital Hepatic Hemangioma: Lessons from a Case Series
Background: Congenital hepatic hemangiomas (CHHs) are typically considered rapidly involuting tumors, similar to their cutaneous counterparts (RICHs). However, non-involuting tumors remain poorly characterized. This study examines the evolutionary patterns and management strategies for non-involuting congenital hepatic hemangiomas (NICHHs). Methods: We conducted a retrospective review of clinical, imaging, histological, and genetic data of children diagnosed with NICHH—defined as showing no signs of involution for at least 18 months—between 1991 and 2022. Results: Seven patients (five females, two males) were identified. The median age at diagnosis was 42 days (range: 0–1440). Five patients had asymptomatic lesions, predominantly located in the right hepatic lobe. Histologic confirmation was available in three cases, and a GNAQ gene mutation was identified in one. The median follow-up period was 75 months (range: 35–191). Three patients with giant NICHH were treated with sirolimus, resulting in partial response in two cases and lesion stabilization in one. The four untreated patients showed diverse evolutionary patterns, including delayed involution and tardive growth. Conclusions: NICHH lesions demonstrate distinct long-term evolution. Accurate diagnosis and regular monitoring are essential to avoid unnecessary interventions. Sirolimus may offer a promising non-surgical treatment for select patients, particularly those with giant lesions.
Open AccessNon-Involuting Congenital Hepatic Hemangioma: Lessons from a Case Series
Background: Congenital hepatic hemangiomas (CHHs) are typically considered rapidly involuting tumors, similar to their cutaneous counterparts (RICHs). However, non-involuting tumors remain poorly characterized. This study examines the evolutionary patterns and management strategies for non-involuting congenital hepatic hemangiomas (NICHHs). Methods: We conducted a retrospective review of clinical, imaging, histological, and genetic data of children diagnosed with NICHH—defined as showing no signs of involution for at least 18 months—between 1991 and 2022. Results: Seven patients (five females, two males) were identified. The median age at diagnosis was 42 days (range: 0–1440). Five patients had asymptomatic lesions, predominantly located in the right hepatic lobe. Histologic confirmation was available in three cases, and a GNAQ gene mutation was identified in one. The median follow-up period was 75 months (range: 35–191). Three patients with giant NICHH were treated with sirolimus, resulting in partial response in two cases and lesion stabilization in one. The four untreated patients showed diverse evolutionary patterns, including delayed involution and tardive growth. Conclusions: NICHH lesions demonstrate distinct long-term evolution. Accurate diagnosis and regular monitoring are essential to avoid unnecessary interventions. Sirolimus may offer a promising non-surgical treatment for select patients, particularly those with giant lesions.
- Open Access
- 28 May 2025
- Published by MDPI AG in Preprints.org
Non-Involuting Congenital Hepatic Hemangioma: Natural History and Management
Background: Focal liver hemangiomas have traditionally been considered as rapidly involuting tumors, akin to their cutaneous counterparts (RICH). However, non-involuting tumors remain poorly investigated and inadequately understood. This study explores the evolution patterns and management strategies for non-involuting congenital hepatic hemangiomas (NICHH). Methods: We conducted a retrospective review of clinical, imaging, histological, and genetic data of children diagnosed with NICHH (defined as having no signs of involution for at least 18 months) from 1991 to 2022. Results: We included 7 patients (5 females and 2 males) diagnosed with NICHH. The median age at diagnosis was 42 days (range: 0-1440). Seventy-one percent of lesions were asymptomatic, with the right hepatic lobe being the most common location (71.4%). Histological analysis was available in 3 patients confirming the diagnosis of CHH. A genetic study conducted in one patient identified a mutation in GNAQ gene. The median follow-up duration was of 75 months (range: 35-191). During follow-up, 3 patients with giant NICHH received sirolimus treatment, resulting in a partial response in 2 patients, while the lesion in the other patient remained stable. The 4 untreated patients exhibited various evolutionary patterns, some of which had not been previously described. Conclusions: This is the first case series to examine the long -term evolution of NICHH. Accurate diagnosis and periodic follow-up of these lesions can prevent unnecessary aggressive treatments. Sirolimus may offer a promising option for reducing the size or accelerate the involution of NICHH.
- 28 May 2025
- Published by MDPI AG in Preprints.org
Open AccessNon-Involuting Congenital Hepatic Hemangioma: Natural History and Management
Background: Focal liver hemangiomas have traditionally been considered as rapidly involuting tumors, akin to their cutaneous counterparts (RICH). However, non-involuting tumors remain poorly investigated and inadequately understood. This study explores the evolution patterns and management strategies for non-involuting congenital hepatic hemangiomas (NICHH). Methods: We conducted a retrospective review of clinical, imaging, histological, and genetic data of children diagnosed with NICHH (defined as having no signs of involution for at least 18 months) from 1991 to 2022. Results: We included 7 patients (5 females and 2 males) diagnosed with NICHH. The median age at diagnosis was 42 days (range: 0-1440). Seventy-one percent of lesions were asymptomatic, with the right hepatic lobe being the most common location (71.4%). Histological analysis was available in 3 patients confirming the diagnosis of CHH. A genetic study conducted in one patient identified a mutation in GNAQ gene. The median follow-up duration was of 75 months (range: 35-191). During follow-up, 3 patients with giant NICHH received sirolimus treatment, resulting in a partial response in 2 patients, while the lesion in the other patient remained stable. The 4 untreated patients exhibited various evolutionary patterns, some of which had not been previously described. Conclusions: This is the first case series to examine the long -term evolution of NICHH. Accurate diagnosis and periodic follow-up of these lesions can prevent unnecessary aggressive treatments. Sirolimus may offer a promising option for reducing the size or accelerate the involution of NICHH.